1 Introduction to Research & Analysis Reports
1.1 Bladder Cancer Targeted Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bladder Cancer Targeted Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bladder Cancer Targeted Drug Overall Market Size
2.1 Global Bladder Cancer Targeted Drug Market Size: 2022 VS 2029
2.2 Global Bladder Cancer Targeted Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bladder Cancer Targeted Drug Players in Global Market
3.2 Top Global Bladder Cancer Targeted Drug Companies Ranked by Revenue
3.3 Global Bladder Cancer Targeted Drug Revenue by Companies
3.4 Top 3 and Top 5 Bladder Cancer Targeted Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Bladder Cancer Targeted Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bladder Cancer Targeted Drug Players in Global Market
3.6.1 List of Global Tier 1 Bladder Cancer Targeted Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Bladder Cancer Targeted Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Bladder Cancer Targeted Drug Market Size Markets, 2022 & 2029
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type – Global Bladder Cancer Targeted Drug Revenue & Forecasts
4.2.1 By Type – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
4.2.2 By Type – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
4.2.3 By Type – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Bladder Cancer Targeted Drug Revenue & Forecasts
5.2.1 By Application – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
5.2.2 By Application – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
5.2.3 By Application – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
6.2 By Region – Global Bladder Cancer Targeted Drug Revenue & Forecasts
6.2.1 By Region – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
6.2.2 By Region – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
6.2.3 By Region – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.3.2 US Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.3 Canada Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.4 Mexico Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Bladder Cancer Targeted Drug Revenue, 2018-2029
6.4.2 Germany Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.3 France Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.4 U.K. Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.5 Italy Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.6 Russia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.7 Nordic Countries Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.8 Benelux Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Bladder Cancer Targeted Drug Revenue, 2018-2029
6.5.2 China Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.3 Japan Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.4 South Korea Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.5 Southeast Asia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.6 India Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.6.2 Brazil Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6.3 Argentina Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Bladder Cancer Targeted Drug Revenue, 2018-2029
6.7.2 Turkey Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.3 Israel Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.5 UAE Bladder Cancer Targeted Drug Market Size, 2018-2029
7 Bladder Cancer Targeted Drug Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Bladder Cancer Targeted Drug Major Product Offerings
7.1.4 Pfizer Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Company Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Bladder Cancer Targeted Drug Major Product Offerings
7.2.4 Merck KGaA Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Bladder Cancer Targeted Drug Major Product Offerings
7.3.4 Roche Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 Astellas
7.4.1 Astellas Company Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Bladder Cancer Targeted Drug Major Product Offerings
7.4.4 Astellas Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News & Latest Developments
7.5 Janssen Biotech
7.5.1 Janssen Biotech Company Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Bladder Cancer Targeted Drug Major Product Offerings
7.5.4 Janssen Biotech Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Major Product Offerings
7.6.4 Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Bladder Cancer Targeted Drug Major Product Offerings
7.7.4 Merck & Co. Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Bladder Cancer Targeted Drug Major Product Offerings
7.8.4 Gilead Sciences Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の膀胱がん標的薬市場予測2023-2029：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他 |
| 【英語タイトル】Bladder Cancer Targeted Drug Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5720 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：66 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の膀胱がん標的薬市場規模と予測を収録しています。・世界の膀胱がん標的薬市場：売上、2018年-2023年、2024年-2029年 ・世界の膀胱がん標的薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の膀胱がん標的薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アテゾリズマブ（テセントリク）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 膀胱がん標的薬のグローバル主要企業は、Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、膀胱がん標的薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の膀胱がん標的薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の膀胱がん標的薬市場：タイプ別市場シェア、2022年 ・アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他 世界の膀胱がん標的薬市場：用途別、2018年-2023年、2024年-2029年 世界の膀胱がん標的薬市場：用途別市場シェア、2022年 ・病院、小売薬局、その他 世界の膀胱がん標的薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の膀胱がん標的薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における膀胱がん標的薬のグローバル売上、2018年-2023年 ・主要企業における膀胱がん標的薬のグローバル売上シェア、2022年 ・主要企業における膀胱がん標的薬のグローバル販売量、2018年-2023年 ・主要企業における膀胱がん標的薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences ************************************************************* ・調査・分析レポートの概要 膀胱がん標的薬市場の定義 市場セグメント 世界の膀胱がん標的薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の膀胱がん標的薬市場規模 世界の膀胱がん標的薬市場規模：2022年 VS 2029年 世界の膀胱がん標的薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの膀胱がん標的薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の膀胱がん標的薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他 膀胱がん標的薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、小売薬局、その他 膀胱がん標的薬の用途別グローバル売上・予測 ・地域別市場分析 地域別膀胱がん標的薬市場規模 2022年と2029年 地域別膀胱がん標的薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences ... |
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
This report aims to provide a comprehensive presentation of the global market for Bladder Cancer Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bladder Cancer Targeted Drug. This report contains market size and forecasts of Bladder Cancer Targeted Drug in global, including the following market information:
Global Bladder Cancer Targeted Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Bladder Cancer Targeted Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Atezolizumab (Tecentriq) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Bladder Cancer Targeted Drug include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bladder Cancer Targeted Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bladder Cancer Targeted Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Type, 2022 (%)
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Global Bladder Cancer Targeted Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Bladder Cancer Targeted Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bladder Cancer Targeted Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bladder Cancer Targeted Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bladder Cancer Targeted Drug, market overview.
Chapter 2: Global Bladder Cancer Targeted Drug market size in revenue.
Chapter 3: Detailed analysis of Bladder Cancer Targeted Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bladder Cancer Targeted Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の膀胱がん標的薬市場予測2023-2029：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他] (コード：MMG23JU5720)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の膀胱がん標的薬市場予測2023-2029：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他]についてメールでお問い合わせ |
